NEWS BRIEF: WEX Successfully Completes Cardiac Safety Clinic Trial of Halneuron™
July 13, 2018
Vancouver, BC (March 30, 2018) ‐ WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing HalneuronTM (Tetrodotoxin or TTX) for pain, today announced the successful completion of the thorough electrocardiogram (“ECG”) study of Halneuron conducted in healthy volunteers.
